Perioperative Management of Antiplatelet and Anticoagulant Therapy

Summary Table: General Stop Antiplatelet and Anticoagulant Drug Times Before High-Risk Surgery

---

Introduction

Perioperative management of patients on antiplatelet and anticoagulant therapy often requires balancing the risk of thrombotic complications against the risk of surgical bleeding. Decisions must be individualized based on the type of procedure, bleeding risk, and the patient’s underlying thrombotic risk (e.g., recent stent, high CHA₂DS₂-VASc score, mechanical heart valve, etc.).

This article provides general guidelines that can serve as a starting point for Internal Medicine residents. Always remember to collaborate with cardiology, hematology, and surgical teams when dealing with high-risk or complex cases.

---

Antiplatelet Agents

1. Aspirin (ASA)

• Minor procedures with low bleeding risk: Continue aspirin. The bleeding risk from continuing aspirin is generally manageable, and the risk of thrombosis if stopped can outweigh the benefits in some patients.
• High bleeding risk procedures:
  • Recommended to stop 5–7 days prior to surgery.
  • If the patient has a high cardiovascular risk (e.g., recent myocardial infarction, coronary stent), consider consulting cardiology before discontinuing aspirin.

2. Clopidogrel (Plavix)

• Stop 5–7 days before surgery if the bleeding risk is high and there is no recent stent (especially no recent drug-eluting stent within the last 3–6 months).
• Continue if the patient has high thrombotic risk such as a recent coronary stent (consult cardiology).
• In emergency settings, if clopidogrel was taken within 24 hours, platelet transfusions might be considered to reduce bleeding risk, though this approach is not always effective due to irreversible platelet inhibition.

3. Prasugrel (Effient)

• Has a longer half-life and stronger antiplatelet effect compared to clopidogrel.
• Stop 7 days before surgery to allow sufficient platelet recovery.

4. Ticagrelor (Brilinta)

• Stop 5 days before surgery. Ticagrelor has a faster offset than prasugrel but still requires multiple days for platelet function to recover sufficiently.

---

Anticoagulants

1. Warfarin

• Stop 5 days before surgery to allow the INR to normalize, aiming for an INR < 1.5 in most cases for major surgery.
• Bridging therapy (e.g., low molecular weight heparin) is recommended for patients with high thrombotic risk (e.g., mechanical heart valves, recent VTE, high-risk atrial fibrillation).

2. Direct Oral Anticoagulants (DOACs)

Factor Xa Inhibitors

• Rivaroxaban, Apixaban, Edoxaban
  • For high bleeding risk surgeries: Stop 48 hours before.
  • For low bleeding risk procedures: Stop 24 hours before.

Dabigatran (Direct Thrombin Inhibitor)

• CrCl ≥ 50 mL/min: Stop 2–3 days before surgery.
• CrCl < 50 mL/min: Stop 4–5 days before surgery.
• Due to its predominant renal excretion, timing depends on renal function.

3. Low Molecular Weight Heparin (LMWH) (e.g., Enoxaparin, Dalteparin)

• For once-daily dosing, hold the dose 24 hours before a major procedure.
• If twice-daily dosing for therapeutic anticoagulation, consult guidelines or hematology to adjust timing (typically skip the previous day’s doses and ensure at least 24 hours have passed).

4. Unfractionated Heparin (UFH)

• IV infusion can be discontinued 4–6 hours before surgery given its short half-life (about 60–90 minutes).
• Monitor aPTT or factor Xa levels if needed, especially in high-risk patients.

---

Special Considerations

1. Emergency Surgery
   • If a patient has been on clopidogrel or prasugrel within 24 hours, platelet transfusions may be considered if critical bleeding risk is anticipated. However, the effect of transfused platelets can still be inhibited by circulating drug, making this strategy of limited effectiveness.
2. Neuraxial Procedures (Spinal/Epidural Anesthesia)
   • Follow specific ASRA (American Society of Regional Anesthesia) guidelines regarding timing of medication discontinuation and re-initiation to reduce the risk of spinal or epidural hematoma.
3. Cardiac Stents
   • If the patient received a stent within the past 3–6 months, always consult a cardiologist before stopping any antiplatelet medication. Premature discontinuation can lead to stent thrombosis, a life-threatening complication.
4. Bridging Considerations
   • High thrombotic risk patients (e.g., mechanical valves, recent VTE, high-risk atrial fibrillation) may need bridging with LMWH or UFH if warfarin is held.
   • DOAC bridging is generally not recommended due to the short half-lives of these agents, which allow for straightforward perioperative management without bridging in most cases.
5. Individualized Risk Assessment
   • Use validated bleeding risk scores (e.g., HAS-BLED) and consider the procedural complexity.
   • Multi-disciplinary approach: collaborate with anesthesia, cardiology, and hematology, especially in borderline cases.

---

Practical Tips for the Internal Medicine Resident

• Plan in advance. Whenever possible, schedule elective surgeries to allow enough time to stop medications safely.
• Assess renal function. For patients on DOACs, especially dabigatran, check creatinine clearance (CrCl).
• Check INR when stopping warfarin. Re-measure INR closer to procedure day to ensure normalization.
• Communicate bridging plans. Coordinate with nursing and pharmacy to ensure LMWH or UFH bridging is managed properly.
• Resume therapy post-procedure. Restart anticoagulants or antiplatelets once hemostasis is secured—this may be as soon as 24 hours post-procedure for lower-risk cases but could be longer for high-bleeding-risk surgeries.

---

Conclusion

Effective perioperative management of antiplatelet and anticoagulant therapy requires a nuanced approach. These guidelines serve as a framework, but clinical judgment and interdisciplinary collaboration are paramount. Always tailor decisions to individual patient factors, including the urgency of the procedure, the patient’s cardiac history, renal function, and overall bleeding versus thrombotic risk.

References and more detailed guidelines are available from:

• American College of Chest Physicians (ACCP) Guidelines
• American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines
• American Society of Regional Anesthesia (ASRA) Guidelines